share_log

Analyzing Agenus (NASDAQ:AGEN) & Voyager Therapeutics (NASDAQ:VYGR)

Analyzing Agenus (NASDAQ:AGEN) & Voyager Therapeutics (NASDAQ:VYGR)

分析阿吉尼亚(纳斯达克:AGEN)和旅行者治疗公司(纳斯达克:VYGR)
Defense World ·  2022/09/17 01:31

Agenus (NASDAQ:AGEN – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

纳斯达克:AGEN-GET评级和旅行者治疗(纳斯达克:VYGR-GET评级)都是小盘医疗公司,但哪种投资更好?我们将根据这两家公司的盈利能力、风险、分析师建议、收益、估值、股息和机构所有权等方面的实力进行比较。

Analyst Recommendations

分析师建议

This is a summary of current ratings and target prices for Agenus and Voyager Therapeutics, as reported by MarketBeat.com.

这是MarketBeat.com报道的Agenus和Voyager治疗公司的当前评级和目标价格的摘要。

Get
到达
Agenus
非亏格
alerts:
警报:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus 0 0 2 0 3.00
Voyager Therapeutics 0 1 1 0 2.50
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
非亏格 0 0 2 0 3.00
旅行者治疗公司 0 1 1 0 2.50

Agenus currently has a consensus target price of $11.00, suggesting a potential upside of 370.09%. Voyager Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 6.54%. Given Agenus' stronger consensus rating and higher possible upside, equities analysts plainly believe Agenus is more favorable than Voyager Therapeutics.

Agenus目前的共识目标价为11.00美元,暗示潜在上涨370.09%。Voyager治疗公司的共识目标价为7.00美元,这意味着潜在的上涨6.54%。考虑到Agenus更高的共识评级和更高的可能上行空间,股票分析师显然认为Agenus比Voyager治疗公司更有利。

Institutional & Insider Ownership

机构与内部人持股

51.9% of Agenus shares are held by institutional investors. Comparatively, 59.4% of Voyager Therapeutics shares are held by institutional investors. 4.8% of Agenus shares are held by company insiders. Comparatively, 22.0% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Agenus 51.9%的股份由机构投资者持有。相比之下,Voyager治疗公司59.4%的股份由机构投资者持有。Agenus 4.8%的股份由公司内部人士持有。相比之下,Voyager治疗公司22.0%的股份由公司内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一只股票的长期表现将好于大盘。

Earnings & Valuation

收益与估值

This table compares Agenus and Voyager Therapeutics' revenue, earnings per share and valuation.

此表比较了Agenus和Voyager治疗公司的收入、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agenus $295.67 million 2.24 -$23.93 million $0.10 23.40
Voyager Therapeutics $37.42 million 6.79 -$71.20 million ($1.58) -4.16
总收入 价格/销售额比 净收入 每股收益 市盈率
非亏格 2.9567亿美元 2.24 -2,393万美元 $0.10 23.40
旅行者治疗公司 3,742万美元 6.79 -7,120万美元 ($1.58) -4.16

Agenus has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Agenus的收入和收益比Voyager Treeutics高。Voyager治疗公司的市盈率低于Agenus,这表明它目前是两只股票中更负担得起的一只。

Volatility and Risk

波动性和风险

Agenus has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Agenus的贝塔系数为1.17,这表明其股价的波动性比标准普尔500指数高17%。相比之下,Voyager Treeutics的贝塔系数为1.11,这表明其股价的波动性比标准普尔500指数高11%。

Profitability

盈利能力

This table compares Agenus and Voyager Therapeutics' net margins, return on equity and return on assets.

此表比较了Agenus和Voyager治疗公司的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Agenus 3.07% 11.65% 0.81%
Voyager Therapeutics -193.48% -75.15% -30.24%
净利润率 股本回报率 资产回报率
非亏格 3.07% 11.65% 0.81%
旅行者治疗公司 -193.48% -75.15% -30.24%

Summary

摘要

Agenus beats Voyager Therapeutics on 11 of the 14 factors compared between the two stocks.

在两只股票之间的14个因素中,Agenus在11个因素上击败了Voyager Treeutics。

About Agenus

关于Agenus

(Get Rating)

(获取评级)

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus Inc.是一家临床阶段的免疫肿瘤学公司,在美国和国际上发现和开发免疫肿瘤学产品。该公司提供Retrocell Display,这是一个抗体表达平台,用于识别完全人类和人源化的单抗;以及展示技术。它开发的疫苗项目包括预噬菌体候选疫苗;以及基于皂素的疫苗佐剂QS-21刺激剂。该公司还开发了已经完成第二阶段临床试验的抗PD-1拮抗剂Balstilimab,用于治疗二线宫颈癌的第二阶段临床试验;正在进行第一阶段临床试验的抗CTLA-4单特异性抗体AGEN1181;处于第一阶段临床试验的抗CD137单特异性抗体AGEN2373;已经完成第一阶段临床试验的肿瘤微环境调节抗CD73/转化生长因子陷阱双功能抗体AGEN1423;抗TIGIT双特异性抗体AGEN1777;以及人类单抗AGEN1327。此外,该公司还开发了抗GITR单特异性抗体INCAGN1876、抗OX40单特异性抗体INCAGN1949、抗TIM-3单特异性抗体INCAGN2390、抗LAG-3单特异性抗体INCAGN2385、针对ILT4的单特异性抗体MK-4830、处于实体瘤、多发性骨髓瘤和病毒性ARDS第一阶段临床试验的iNKT细胞AGEN797,以及治疗恶性血液病和多发性骨髓瘤/B细胞的第一代抗CTLA-4单特异性抗体AGEN1884。Agenus公司以ASV、Agenus、AutoSynVax、EVAMPLIX、MINK、PSV、PhosPhoSynVax、Prophage、Retrocell Display和Stimulon商标运营。它与Incell Corporation、Merck Sharpe&Dohme、Recepta Biophma SA和Gilead Sciences进行了合作, 该公司前身为Antigenics Inc.,并于2011年1月更名为Agenus Inc.。Agenus Inc.成立于1994年,总部设在马萨诸塞州列克星敦。

About Voyager Therapeutics

关于旅行者治疗公司

(Get Rating)

(获取评级)

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Voyager治疗公司是一家基因治疗公司,专注于治疗和下一代平台技术的开发。该公司的主要临床候选药物是VY-AADC,它正在进行治疗帕金森病的开放标签第一阶段临床试验。它的临床前计划包括用于治疗肌萎缩侧索硬化症的VY-SOD102;用于亨廷顿病的VY-HTT01;用于Friedreich共济失调的VY-FXN01;以及用于治疗包括阿尔茨海默病、进行性核上性瘫痪和额颞部痴呆以及脊髓性肌萎缩症在内的各种疾病的Tau计划。该公司与辉瑞的Neurocrine生物科学公司和A.G.诺华制药公司就腺相关病毒基因治疗产品的研究、开发和商业化达成合作和许可协议。Voyager治疗公司成立于2013年,总部设在马萨诸塞州剑桥市。

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Agenus Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Agenus和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发